US FDA Approves Shorla Oncology’s Nelarabine Injection to Treat T-Cell Leukemia
Nelarabine Injection, an oncology drug developed by Shorla Oncology, has received US FDA approval for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL). Nelarabine Injection offers patients a substitute for a product that has historically been scarce. Sharon Cunningham, CEO and co-founder of Shorla Oncology, said that they are very […]
Continue Reading